Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Volume 13, 2019 - Issue 6
Submit an article Journal homepage
1,703
Views
5
CrossRef citations to date
0
Altmetric
Editorial

HDAC inhibitors in liver cancer: which route to take?

Tobias KiesslichDepartment of Internal Medicine I, Paracelsus Medical University, Salzburger Landeskliniken (SALK), Salzburg, Austria;Institute of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, AustriaView further author information
&
Daniel NeureiterInstitute of Pathology, Paracelsus Medical University/Salzburger Landeskliniken (SALK), Salzburg, Austria;Cancer Cluster Salzburg, Salzburg, AustriaCorrespondence[email protected]
View further author information
Pages 515-517 | Received 10 Dec 2018, Accepted 05 Apr 2019, Published online: 17 Apr 2019

References

  • Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. Nat Rev Genet. 2016;17(8):487–500.
  • McClure JJ, Li X, Chou CJ. Advances and challenges of HDAC inhibitors in cancer therapeutics. Adv Cancer Res. 2018;138:183–211.
  • Zhao J, Gray SG, Greene CM, et al. Unmasking the pathological and therapeutic potential of histone deacetylases for liver cancer. Expert Rev Gastroenterol Hepatol. 2019;13(3):247–256.
  • Quint K, Agaimy A, Di Fazio P, et al. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch. 2011;459(2):129–139.
  • Hardy T, Mann DA. Epigenetics in liver disease: from biology to therapeutics. Gut. 2016;65(11):1895–1905.
  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
  • Bitzer M, Horger M, Giannini EG, et al. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study. J Hepatol. 2016;65(2):280–288.
  • Yeo W, Chung HC, Chan SL, et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo phase II consortium and the cancer therapeutics research group. J Clin Oncol. 2012;30(27):3361–3367.
  • Tak WY, Ryoo BY, Lim HY, et al. Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. Invest New Drugs. 2018;36(6):1072–1084.
  • Montalbano R, Waldegger P, Quint K, et al. Endoplasmic reticulum stress plays a pivotal role in cell death mediated by the pan-deacetylase inhibitor panobinostat in human hepatocellular cancer cells. Transl Oncol. 2013;6(2):143–157.
  • Di Fazio P, Waldegger P, Jabari S, et al. Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer. Oncotarget. 2016;7(20):28998–29010.
  • Henrici A, Montalbano R, Neureiter D, et al. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. Mol Carcinog. 2015;54(8):585–597.
  • Kim HS, Shen Q, Nam SW, et al. Their regulatory MicroRNAs in hepatocarcinogenesis. J Korean Med Sci. 2015;30(10):1375–1380.
  • Griffiths EA, Gore SD. Epigenetic therapies in MDS and AML. Adv Exp Med Biol. 2013;754:253–283.
  • Jueliger S, Lyons J, Cannito S, et al. Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma. Epigenetics. 2016;1–12:709–720.
  • Liu M, Zhang L, Li H, et al. Integrative epigenetic analysis reveals therapeutic targets to the DNA methyltransferase inhibitor guadecitabine (SGI-110) in hepatocellular carcinoma. Hepatology. 2018;68(4):1412–1428.
  • Hlady RA, Robertson KD. A three-pronged epigenetic approach to the treatment of hepatocellular carcinoma. Hepatology. 2018;68(4):1226–1228.
  • Su Y, Hopfinger NR, Nguyen TD, et al. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors. J Exp Clin Cancer Res. 2018;37(1):314.
  • Barros-Silva D, Marques CJ, Henrique R, et al. Profiling DNA methylation based on next-generation sequencing approaches: new insights and clinical applications. Genes (Basel). 2018;9(9):429.
  • de Lera AR, Ganesan A. Epigenetic polypharmacology: from combination therapy to multitargeted drugs. Clin Epigenetics. 2016;8:105.
  • Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov. 2017;16(2):101–114.
  • Ding P, Luo J, Liang C, et al. Discovering synergistic drug combination from a computational perspective. Curr Top Med Chem. 2018;18(12):965–974.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.